Jingkun Zeng

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding.

Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding.

Journal: Nature
Published: August 14, 2026

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding.

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding.

Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026

Amplified genome editing by in vivo editor production.

Amplified genome editing by in vivo editor production.

Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding.

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding.

Journal: Nature
Published: November 04, 2025

Endogenous p21 levels protect genomic stability by suppressing both excess and restrained nascent DNA syntheses.

Endogenous p21 levels protect genomic stability by suppressing both excess and restrained nascent DNA syntheses.

Journal: Science advances
Published: October 08, 2025

Bacterial effectors mediate kinase reprogramming through mimicry of conserved eukaryotic motifs.

Bacterial effectors mediate kinase reprogramming through mimicry of conserved eukaryotic motifs.

Journal: EMBO reports
Published: October 10, 2024

The DNA replication checkpoint prevents PCNA/RFC depletion to protect forks from HLTF-induced collapse in human cells.

The DNA replication checkpoint prevents PCNA/RFC depletion to protect forks from HLTF-induced collapse in human cells.

Journal: Molecular cell
Published: October 07, 2024

Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication.

Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication.

Journal: Cell
Published: March 20, 2022

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 29, 2021

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Journal: The British journal of dermatology
Published: June 17, 2021

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.

Journal: The Biochemical journal
Published: April 29, 2021

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.

Journal: The Biochemical journal
Published: April 06, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026